# AASUR in High Risk Prostate Cancer

> **NCT02772588** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 64 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** ARN-509
- **DRUG:** Abiraterone
- **DRUG:** Leuprolide
- **RADIATION:** stereotactic, ultra-fractionated radiotherapy

## Key facts

- **NCT ID:** NCT02772588
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-12
- **Primary completion:** 2026-01-22
- **Final completion:** 2026-01-22
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02772588

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02772588, "AASUR in High Risk Prostate Cancer". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT02772588. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*